Hydrochlorothiazide And Triamterene

Introduction Overview

Generic Name

hydrochlorothiazide and triamterene

Brand Name

Dyazide, Maxzide, Maxzide-25

Dosage Form

oral capsule, oral tablet

Drug Class

Potassium sparing diuretics with thiazides

Pharmacokinetics

Absorption: Hydrochlorothiazide and triamterene combination is administered orally, with both components exhibiting good gastrointestinal absorption. Hydrochlorothiazide is rapidly and efficiently absorbed from the gastrointestinal tract with peak plasma concentrations observed within 2 to 5 hours post-dose. Triamterene is also absorbed from the gut but displays variable bioavailability due to extensive first-pass metabolism. Food intake does not significantly affect hydrochlorothiazide absorption but may alter triamterene absorption slightly. Clinical studies have demonstrated that steady-state plasma levels of both drugs are attained with repeated dosing, providing reliable therapeutic action.

Distribution: Hydrochlorothiazide distributes moderately into body tissues, binding minimally to plasma proteins (~40%). It crosses the placental barrier but to a limited extent, and does not readily cross the blood-brain barrier. Triamterene is highly protein-bound (~60-90%) and distributes into extracellular fluid with moderate volume of distribution. Both drugs accumulate primarily in the kidney where their diuretic action is exerted. The degree of distribution can be influenced by renal function and plasma albumin levels.

Metabolism: Hydrochlorothiazide undergoes minimal hepatic metabolism and is largely excreted unchanged in the urine, indicating limited biotransformation pathways. Triamterene undergoes substantial hepatic metabolism predominantly via cytochrome P450 enzymes to active and inactive metabolites such as hydroxytriamterene and N-acetyltriamterene. These metabolites have biological activity contributing to the overall diuretic effect. Hepatic impairment can alter the metabolism of triamterene and thus impact drug levels.

Elimination: The elimination half-life of hydrochlorothiazide is approximately 6 to 15 hours, with renal clearance being the primary route of excretion. Triamterene has a half-life of roughly 7 to 17 hours and is eliminated mainly via renal and fecal routes. Both drugs require functional renal systems for efficient clearance. Impaired renal function can prolong elimination half-life and increase the risk of accumulation, necessitating dosage adjustments. Monitoring of renal function is essential during therapy to avoid toxicity.

Dosage Forms

Available Dosage Forms: Hydrochlorothiazide and triamterene are combined in oral formulations available as capsules and tablets. Specifically, the available dosage forms include:
- Oral capsule: 25 mg hydrochlorothiazide - 37.5 mg triamterene
- Oral tablet: 25 mg hydrochlorothiazide - 37.5 mg triamterene
- Oral tablet: 50 mg hydrochlorothiazide - 75 mg triamterene

Dosages for Adults and Adolescents: The usual adult dose for treatment of edema and hypertension consists of hydrochlorothiazide 25 to 50 mg combined with triamterene 37.5 to 100 mg administered once daily orally. Patients who develop hypokalemia on hydrochlorothiazide alone may be transitioned directly to the combination therapy at equivalent dosages (e.g., hydrochlorothiazide 50 mg with triamterene 75 mg). For patients at high risk of hypokalemia (e.g., those taking digitalis, history of arrhythmias), initial therapy with lower doses (25 mg HCTZ/37.5 mg triamterene) is recommended. Dosing modifications may be needed based on therapeutic response and side effects.

Specific Patient Populations: Use in pediatric patients under 18 years is not approved due to lack of safety and efficacy data. Caution is advised in elderly patients and those with impaired renal or hepatic function, as these conditions can alter pharmacokinetics and increase potassium retention risks. Dosage adjustments or close monitoring is warranted. In pregnancy, the safety profile is not well established; clinicians must weigh benefits and risks. Breastfeeding is contraindicated during therapy due to drug excretion in milk and potential adverse neonatal effects.

Mechanism Of Action

Hydrochlorothiazide and triamterene represent a synergistic combination of diuretics with complementary mechanisms of action targeting renal tubular electrolyte transport to promote natriuresis while conserving potassium. Hydrochlorothiazide is a thiazide diuretic that primarily inhibits the sodium-chloride symporter located in the distal convoluted tubule of the nephron. By blocking this transporter, hydrochlorothiazide reduces the reabsorption of sodium and chloride ions, leading to increased urinary excretion of sodium, chloride, and water. The consequent diuresis decreases extracellular fluid volume, thus lowering blood pressure and reducing edema.

Triamterene is a potassium-sparing diuretic acting on the collecting ducts of the nephron. It blocks epithelial sodium channels (ENaC) in the distal nephron, inhibiting sodium reabsorption at this site without promoting potassium loss. By preventing sodium reabsorption in the collecting duct, triamterene decreases potassium excretion, counteracting the hypokalemia commonly induced by thiazide diuretics. This mechanism preserves potassium balance, an important clinical advantage in patients prone to electrolyte disturbances.

Together, this fixed-dose combination achieves effective diuresis and blood pressure reduction while minimizing the risk of hypokalemia, a frequent adverse effect of thiazide monotherapy. The combination is particularly beneficial in hypertensive patients at risk of potassium deficiency and in edema states where fluid removal is required without excessive potassium loss. Clinical trials have demonstrated the efficacy of this drug combination in reducing systolic and diastolic blood pressures and improving fluid balance in patients with hypertension or fluid retention.

Comparatively, other diuretics such as loop diuretics act earlier in the nephron with more potent diuresis but greater potassium loss. Spironolactone, another potassium-sparing agent, acts via aldosterone antagonism, contrasting with the direct sodium channel blockade of triamterene. The combination of hydrochlorothiazide with triamterene offers a balanced approach leveraging thiazide-induced natriuresis and triamterene’s potassium conservation to optimize patient outcomes. Ongoing research supports its use as initial or adjunctive therapy in managing hypertension and edema with enhanced safety profiles.

Pharmacological Actions

Inhibits sodium and chloride reabsorption in distal convoluted tubule by hydrochlorothiazide
Blocks epithelial sodium channels (ENaC) in the collecting tubules by triamterene
Promotes diuresis and natriuresis while conserving potassium ions
Reduces extracellular fluid volume contributing to lowered blood pressure
Mitigates hypokalemia typically induced by thiazide diuretics
Exerts mild vasodilatory effects improving peripheral resistance
Increases urinary excretion of sodium, chloride, and water
Preserves potassium and hydrogen ion balance, decreasing risk of metabolic alkalosis
Modulates electrolyte transport without significantly altering calcium excretion
Acts synergistically to provide balanced diuretic effect with improved safety
Can improve cardiac workload by reducing intravascular volume
Useful in patients with hypertension concomitant with fluid retention
Maintains serum potassium within physiological range during diuretic therapy
Reduces edema associated with congestive heart failure, hepatic cirrhosis, or renal disorders
Minimal effect on magnesium handling, requiring monitoring in prolonged therapy

Therapeutic Or Clinical Uses

Treatment of essential hypertension to lower elevated blood pressure
Management of edema associated with congestive heart failure
Treatment of edema due to hepatic cirrhosis and nephrotic syndrome
Addresses fluid retention in chronic kidney disease
Used in patients who develop hypokalemia from thiazide diuretic monotherapy
Prevents potassium depletion during long-term diuretic therapy
Adjunctive treatment in patients with high cardiovascular risk requiring potassium conservation
Useful in patients with history of cardiac arrhythmias susceptible to hypokalemia
Reserved for initial or maintenance therapy in edema and hypertension
Can be combined with other antihypertensive agents for additive effects
Alternative to spironolactone or amiloride in potassium-sparing diuretic therapy
Management of fluid overload states unresponsive to single-agent diuretics
Improves symptoms and outcomes in patients with salt-sensitive hypertension
Facilitates electrolyte homeostasis during treatment of hypertensive emergencies
Offers oral therapy option with convenient once-daily dosing

Side Or Adverse Effects

Hyperkalemia characterized by nausea, muscle weakness, and irregular heartbeat
Hypokalemia symptoms including muscle cramps, constipation, and palpitations
Gastrointestinal disturbances such as nausea, vomiting, diarrhea, and constipation
Dizziness and headache potentially from blood pressure reduction
Blurred vision or visual disturbances reported in some patients
Dry mouth and dehydration during excessive diuresis
Electrolyte imbalances including hyponatremia and metabolic alkalosis
Photosensitivity increasing risk of skin rash or sunburn, requiring sun protection
Allergic reactions ranging from rash to severe anaphylaxis in rare cases
Lupus-like syndrome with muscle or joint pain and characteristic rash
Pancreatitis and liver enzyme elevations reported rarely
Kidney function impairment with reduced urine output and swelling
Cardiac arrhythmias secondary to electrolyte disturbances
Fatigue, weakness, or light-headedness especially in elderly or volume-depleted patients
Electrolyte disturbances causing neurologic symptoms such as tingling or numbness

Precautions

Use cautiously in patients with impaired renal function or kidney disease
Monitor serum potassium and electrolytes regularly during therapy
Avoid use in patients with hyperkalemia or potassium-sparing medication overlap
Screen for sulfonamide allergy prior to initiation due to hydrochlorothiazide component
Adjust dose in elderly patients to prevent volume depletion and electrolyte imbalance
Avoid dehydration, particularly during hot weather or vigorous exercise
Use with caution in diabetic patients as thiazides may alter glucose tolerance
Monitor for signs of hypotension especially in patients on multiple antihypertensives
Evaluate liver function periodically due to rare hepatotoxicity risk
Advise avoidance of potassium supplements, salt substitutes, or high potassium diets unless directed
Consider alternative agents in patients with history of gout due to risk of exacerbation
Discontinue prior to major surgery or anesthesia as per physician guidance
Use caution in patients with electrolyte abnormalities or endocrine disorders
Avoid use during pregnancy and breastfeeding unless benefits outweigh risks
Educate patient on recognizing signs of electrolyte imbalance or allergic reactions

Warnings

Contraindicated in patients with anuria or inability to urinate
Do not use in patients with hyperkalemia or elevated serum potassium levels
Avoid concomitant use with other potassium-sparing diuretics due to hyperkalemia risk
Can cause life-threatening hyperkalemia in renal impairment, diabetes, or severe illness
Risk of severe allergic reactions including Stevens-Johnson syndrome
May induce electrolyte disturbances leading to arrhythmias or cardiac arrest
Potentially causes photosensitivity and increases risk of skin malignancies
Use with caution in patients with history of systemic lupus erythematosus
Withdrawal may cause rebound hypertension or fluid retention, taper appropriately
Monitor closely for signs of pancreatitis or hepatic dysfunction
Avoid sudden discontinuation without physician supervision
Risk of severe hypotension and syncope especially with volume depletion
Use is not recommended in pediatric population under 18 years old
May impair glucose tolerance necessitating monitoring in diabetic patients
Concomitant NSAID use may decrease diuretic and antihypertensive effect

Contraindication

Known hypersensitivity to hydrochlorothiazide, triamterene, or sulfonamide-derived drugs
Patients with anuria or severe renal impairment
Hyperkalemia or elevated serum potassium concentrations
Concurrent use with other potassium-sparing diuretics such as amiloride or spironolactone
Inability to urinate or significant urinary tract obstruction
History of allergic reaction or angioedema related to the drug components
Pregnancy when potential risks outweigh the benefits (caution advised)
Severe hepatic disease with cholestasis or jaundice
Patients on potassium supplements or salt substitutes containing potassium, unless supervised
Marked hypercalcemia or hyponatremia
Electrolyte imbalance not corrected prior to therapy initiation
Use in pediatric patients under 18 due to absence of safety data
Hypersensitivity to other sulfonamide-derived drugs
Severe hypotension or volume depletion without stabilization
Concurrent use of medications causing hyperkalemia without monitoring

Drug Interactions

Potassium supplements and potassium-containing salt substitutes increasing hyperkalemia risk
Other potassium-sparing diuretics (amiloride, spironolactone) potentiating hyperkalemia
ACE inhibitors (e.g., lisinopril, enalapril) augmenting potassium retention
Nonsteroidal anti-inflammatory drugs (NSAIDs) reducing diuretic and antihypertensive efficacy
Lithium clearance reduced by thiazides raising lithium toxicity risk
Digoxin toxicity enhanced by hypokalemia induced by thiazide component
Chlorpropamide and other antidiabetic agents affected via altered glucose metabolism
Corticosteroids causing additive electrolyte disturbances
Amphotericin B and other nephrotoxic drugs increasing risk of renal impairment
Blood thinners potentially interacting to alter bleeding risk
Methenamine metabolism or urinary antiseptic efficacy may be influenced
Laxatives can exacerbate electrolyte disturbances
Drugs altering heart rhythm can have additive arrhythmogenic risks
Concomitant use of other antihypertensives requiring blood pressure monitoring
Effects on electrolyte balance may impact neuromuscular blocking agents

Preparations Of The Drug

Hydrochlorothiazide 25 mg and triamterene 37.5 mg oral capsules
Hydrochlorothiazide 25 mg and triamterene 37.5 mg oral tablets
Hydrochlorothiazide 50 mg and triamterene 75 mg oral tablets
Fixed-dose combination formulations facilitating once-daily dosing
Available in branded preparations such as Dyazide, Maxzide, and Maxzide-25
Formulations designed to balance diuretic efficacy and potassium conservation
Tablets and capsules formulated for consistent absorption and bioavailability
Products supplied in standard counts for outpatient prescription use
Packaging options include blister packs and bottles with child-resistant caps
Manufactured under controlled conditions ensuring stability and potency